{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T14:22:29Z","timestamp":1720534949690},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6307,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1093\/annonc\/mdf662","type":"journal-article","created":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T02:07:34Z","timestamp":1327025254000},"page":"211-216","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S4","title":["Advances in the treatment of non-Hodgkin's lymphoma"],"prefix":"10.1016","volume":"13","author":[{"given":"T.","family":"Cerny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1093\/annonc\/mdf662_bb0005","first-page":"212","article-title":"Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease (HD) treated with a modified BEACOPP regimen is probably related to the combination of gemcitabine and bleomycin","volume":"13","author":"Bredenfeld","year":"2002","journal-title":"Ann Oncol"},{"issue":"Suppl. 2","key":"10.1093\/annonc\/mdf662_bb0010","first-page":"181","article-title":"Fludarabine versus CVP in newly diagnosed patients with stages III\/IV non-Hodgkin's lymphoma. Final analysis of prospective randomized phase III inter-group study","volume":"13","author":"Marcus","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf662_bb0015","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf662_bb0020","first-page":"294a","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf662_bb0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab as single first-line therapy for patients with follicular lymphomas with a low tumour burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1093\/annonc\/mdf662_bb0030","first-page":"112","article-title":"Maintenance treatment with 2-monthly rituximab after standard weekly \u00d7 4 rituximab induction significantly improves event-free survival in patients with follicular lymphoma","volume":"13","author":"Ghielmini","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf662_bb0035","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf662_bb0040","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf662_bb0045","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf662_bb0050","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"A randomized controlled trial of 90Y-labeled ibritumomab tiuxetan (Zevalin) radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf662_bb0055","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1 Suppl. 2","key":"10.1093\/annonc\/mdf662_bb0060","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/sonc.2002.30152","article-title":"Rituximab in combination with CHOP or fludarabine in low-grade lymphoma","volume":"29","author":"Czuczman","year":"2002","journal-title":"Semin Oncol"},{"issue":"Suppl. 2","key":"10.1093\/annonc\/mdf662_bb0065","first-page":"185","article-title":"A randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma","volume":"13","author":"Zinzani","year":"2002","journal-title":"Ann Oncol"},{"issue":"Suppl. 2","key":"10.1093\/annonc\/mdf662_bb0070","first-page":"186","article-title":"Combined immunochemotherapy (R-FCM) is superior to a fludarabine-containing chemotherapy (FCM) alone in recurrent follicular and mantle cell lymphoma: results of a prospective randomized comparison of the German Low Grade Lymphoma Study Group","volume":"13","author":"Hiddemann","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf662_bb0075","series-title":"CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group randomised trial. Program and abstracts of the 43rd Annual Meeting of the American Society of Hematology","author":"Miller","year":"2001"},{"key":"10.1093\/annonc\/mdf662_bb0080","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf662_bb0085","first-page":"843a","article-title":"A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma","volume":"98","author":"Maloney","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf662_bb0090","first-page":"843a","article-title":"A phase II trial of CHOP followed by Bexxar for treatment of newly diagnosed follicular non-Hodgkin's lymphoma (SWOG 9911)","volume":"98","author":"Press","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf662_bb0095","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/blood.V99.7.2541","article-title":"Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial","volume":"99","author":"Bertoni","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf662_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V99.1.3","article-title":"Gastric marginal zone B-cell lymphomas of MALT type develop along two distinct pathogenetic pathways","volume":"99","author":"Starostik","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf662_bb0105","series-title":"Treatment of Mantle-Cell Lymphoma: Stem-Cell Transplantation, Radioimmunotherapy, and Management of Mantle-Cell Lymphoma Subsets. American Society of Clinical Oncology","first-page":"407","author":"Press","year":"2002"},{"key":"10.1093\/annonc\/mdf662_bb0110","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00001622-200109000-00005","article-title":"Biology and management of mantle cell lymphoma","volume":"13","author":"Leonard","year":"2001","journal-title":"Curr Opin Oncol"},{"issue":"Suppl. 4","key":"10.1093\/annonc\/mdf662_bb0115","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/cncr.10307","article-title":"High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin's lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study","volume":"94","author":"Behr","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf662_bb0120","series-title":"Final report of E1384: CHOP versus CHOP plus radiation for limited stage diffuse aggressive lymphoma. Program and abstracts of the 43rd Annual Meeting of the American Society of Hematology","author":"Horning","year":"2001"},{"issue":"Suppl. 2","key":"10.1093\/annonc\/mdf662_bb0125","first-page":"79","article-title":"Radiotherapy is unnecessary in elderly patients with localized aggressive non-Hodgkin lymphoma: results of the LNH93-4 study","volume":"13","author":"Bonnet","year":"2002","journal-title":"Ann Oncol"},{"issue":"Suppl. 2","key":"10.1093\/annonc\/mdf662_bb0130","first-page":"80","article-title":"Superiority of the ACVBP regimen over a combined treatment with three cycles of CHOP followed by involved field radiotherapy in low risk localized aggressive non-Hodgkin's lymphoma: the LNH93-1 study","volume":"13","author":"Reyes","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf662_bb0135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1093\/annonc\/mdf662_bb0140","first-page":"81","article-title":"Two-weekly CHOP (CHOP-14): new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL)","volume":"13","author":"Pfreundschuh","year":"2002","journal-title":"Ann Oncol"},{"issue":"Suppl. 2","key":"10.1093\/annonc\/mdf662_bb0145","first-page":"82","article-title":"Survival advantage of ACVBP regimen over standard CHOP in the treatment of advanced aggressive non-Hodgkin's lymphoma (NHL). The LNH 93-5 study","volume":"13","author":"Tilly","year":"2002","journal-title":"Ann Oncol"},{"issue":"Suppl. 2","key":"10.1093\/annonc\/mdf662_bb0150","first-page":"28","article-title":"Frontline high-dose chemotherapy (HDC) with autologous stem cell transplantation vs standard CHOP regimen for patients (\u226460 yo) with non IPI high-risk intermediate or high grade lymphomas (NHL). Final results of a ran-domized trial by the GOELAMS","volume":"13","author":"Milpied","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf662_bb0155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/11.suppl_3.117","article-title":"Role of high-dose therapy in diffuse large B-cell lymphoma","volume":"3","author":"Cerny","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf662_bb0160","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1200\/JCO.2001.19.6.1855","article-title":"Primary mediastinal B-cell lymphoma: a review of pathology and management","volume":"19","author":"van Besien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf662_bb0165","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1212\/WNL.58.10.1513","article-title":"A multicenter study of treatment of primary CNS lymphoma","volume":"58","author":"Ferreri","year":"2002","journal-title":"Neurology"},{"key":"10.1093\/annonc\/mdf662_bb0170","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1008371602708","article-title":"Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?","volume":"11","author":"Ruhstaller","year":"2000","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419628607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419628607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/suppl_4\/211\/419015\/mdf662.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T02:30:46Z","timestamp":1582165846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419628607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":34,"alternative-id":["S0923753419628607"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf662","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}